Broadening its footprint in its key market of pulmonary arterial hypertension (PAH), while reducing its dependence on its Tracleer (bosentan) franchise, Actelion Ltd. entered a definitive agreement to acquire CoTherix Inc. for $13.50 per share, or about $420 million. (BioWorld Today)
Broadening its footprint in its key market of pulmonary arterial hypertension (PAH), while reducing its dependence on its Tracleer (bosentan) franchise, Actelion Ltd. entered a definitive agreement to acquire CoTherix Inc. for $13.50 per share, or about $420 million. (BioWorld Today)
Shares in Acambis plc plunged 38 percent on the London Stock Exchange Tuesday on news that the U.S. Department of Health and Human Services is no longer considering its bid for a government contract to supply a stockpile of next-generation smallpox vaccines, based on the modified vaccinia ankara (MVA) vector. (BioWorld International)
Shares in Acambis plc plunged 38 percent on the London Stock Exchange Tuesday on news that the U.S. Department of Health and Human Services is no longer considering its bid for a government contract to supply a stockpile of next-generation smallpox vaccines, based on the modified vaccinia ankara (MVA) vector. (BioWorld International)
